| 1 |
Kitaichi M, Nishimura K, Itoh H, et al. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors [J]. Am J Respir Crit Care Med, 1995, 151(2 Pt 1): 527-533.
|
| 2 |
Taylor JR, Ryu J, Colby TV, et al. Lymphangioleiomyomatosis. Clinical course in 32 patients [J]. N Engl J Med,1990, 323(18): 1254-1260.
|
| 3 |
Gupta N, Lee HS, Ryu JH, et al. The NHLBI LAM registry: prognostic physiologic and radiologic biomarkers emerge from a 15-year prospective longitudinal analysis [J]. Chest, 2019, 155(2): 288-296.
|
| 4 |
Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline [J]. Am J Respir Crit Care Med, 2017, 196(10): 1337-1348.
|
| 5 |
Krymskaya VP, McCormack FX. Lymphangioleiomyomatosis: a monogenic model of malignancy [J]. Annu Rev Med, 2017, 68: 69-83.
|
| 6 |
Goncharova EA, Goncharov DA, Li H, et al. mTORC2 is required for proliferation and survival of TSC2-null cells [J]. Mol Cell Biol, 2011, 31(12): 2484-2498.
|
| 7 |
Kim W, Giannikou K, Dreier JR, et al. A genome-wide association study implicates NR2F2 in lymphangioleiomyomatosis pathogenesis [J]. Eur Respir J, 2019, 53(6): 1900329.
|
| 8 |
Kida Y. Efficacy and safety of sirolimus in lymphangioleiomyomatosis [J]. N Engl J Med, 2011, 365(3): 271.
|
| 9 |
McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: lymphangioleiomyomatosis diagnosis and management [J]. Am J Respir Crit Care Med, 2016, 194(6): 748-761.
|
| 10 |
Li X, Liu X, Zhang L, et al. Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis [J]. Oncotarget, 2017, 8(22): 36628-36638.
|
| 11 |
Himes BE, Obraztsova K, Lian L, et al. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells [J]. PLoS One, 2018, 13(5): e0197105.
|
| 12 |
Parkhitko A, Myachina F, Morrison TA, et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent [J]. Proc Natl Acad Sci U S A, 2011, 108(30): 12455-12460.
|
| 13 |
Zhan Y, Shen L, Xu W, et al. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study [J]. Orphanet J Rare Dis, 2018, 13(1): 34.
|
| 14 |
Ando K, Kurihara M, Kataoka H, et al. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis [J]. Respir Investig, 2013, 51(3): 175-183.
|
| 15 |
Yoon HY, Hwang JJ, Kim DS, et al. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis [J]. Orphanet J Rare Dis, 2018, 13(1): 204.
|
| 16 |
淋巴管肌瘤病共识专家组. 西罗莫司治疗淋巴管肌瘤病专家共识(2018) [J]. 中华结核和呼吸杂志, 2019, 42(2): 92-97.
|
| 17 |
Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment [J]. Am J Respir Crit Care Med, 2006, 173(1): 105-111.
|
| 18 |
Guardia O, Rial Mdel C, Casadei D. Pregnancy under sirolimus-based immunosuppression [J]. Transplantation, 2006, 81(4): 636.
|
| 19 |
Landh E, Moir LM, Gomes Dos Reis L, et al. Inhaled rapamycin solid lipid nano particles for the treatment of lymphangioleiomyomatosis [J]. Eur J Pharm Sci, 2020, 142: 105098.
|
| 20 |
Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis [J]. Eur Respir J, 2010, 35(1): 14-26.
|
| 21 |
Lu C, Lee HS, Pappas GP, et al. A phase II clinical trial of an aromatase inhibitor for postmenopausal women with lymphangioleiomyomatosis [J]. Ann Am Thorac Soc, 2017, 14(6): 919-928.
|
| 22 |
El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, et al. Sirolimus and autophagy inhibition in lymphangioleiomyomatosis: results of a phase I clinical trial [J]. Chest, 2017, 151(6): 1302-1310.
|
| 23 |
El-Chemaly S, Taveira-DaSilva A, Stylianou MP, et al. Statins in lymphangioleiomyomatosis: a word of caution [J]. Eur Respir J, 2009, 34(2): 513-514.
|
| 24 |
Krymskaya VP, Courtwright AM, Fleck V, et al. A phase II clinical trial of the safety of simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex [J]. Respir Med, 2020, 163: 105898.
|
| 25 |
Pimenta SP, Baldi BG, Acencio MM, et al. Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade [J]. J Bras Pneumol, 2011, 37(4): 424-430.
|
| 26 |
Moses MA, Harper J, and Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs [J]. N Engl J Med, 2006, 354(24): 2621-2622.
|
| 27 |
Kim SH, Baek MS, Yoon DS, et al. Vitamin D inhibits expression and activity of matrix metalloproteinase in human lung fibroblasts (HFL-1) cells [J]. Tuberc Respir Dis (Seoul), 2014, 77(2): 73-80.
|
| 28 |
Chang WY, Cane JL, Kumaran M, et al. A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis [J]. Eur Respir J, 2014, 43(4): 1114-1123.
|
| 29 |
Le K, Steagall WK, Stylianou M, et al. Effect of beta-agonists on LAM progression and treatment [J]. Proc Natl Acad Sci U S A, 2018, 115(5): E944-E953.
|
| 30 |
Johnson J, Johnson SR. Cross-sectional study of reversible airway obstruction in LAM: better evidence is needed for bronchodilator and inhaled steroid use [J]. Thorax, 2019, 74(10): 999-1002.
|
| 31 |
Hu S, Wu X, Xu W, et al. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis [J]. Orphanet J Rare Dis, 2019, 14(1): 206.
|
| 32 |
Gupta N, Lee HS, Young LR, et al. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis [J]. Eur Respir J, 2019, 53(4): 1802066.
|
| 33 |
Almoosa KF, Ryu JH, Mendez J, et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications [J]. Chest, 2006, 129(5): 1274-1281.
|
| 34 |
Kurihara M, Mizobuchi T, Kataoka H, et al. A total pleural covering for lymphangioleiomyomatosis prevents pneumothorax recurrence [J]. PLoS One, 2016, 11(9): e0163637.
|
| 35 |
Taveira-DaSilva AM, Jones AM, Julien-Williams P, et al. Severity and outcome of cystic lung disease in women with tuberous sclerosis complex [J]. Eur Respir J, 2015, 45(1): 171-180.
|
| 36 |
Boehm PM, Ghanim BD, Matilla J, et al. Chylothorax in a 32-year-old patient with lymphangioleiomyomatosis after bilateral lung transplant [J]. Ann Thorac Surg, 2018, 105(6): e263-e264.
|
| 37 |
Bee J, Fuller S, Miller S, et al. Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study [J]. Thorax, 2018, 73(4): 369-375.
|
| 38 |
Fine NM, Kushwaha SS. Recent advances in mammalian target of rapamycin inhibitor use in heart and lung transplantation [J]. Transplantation, 2016, 100(12): 2558-2568.
|
| 39 |
El-Chemaly S, Goldberg HJ, Glanville AR. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation? [J]. Expert Rev Respir Med, 2014, 8(6): 657-660.
|
| 40 |
Khawar MU, Yazdani D, Zhu Z, et al. Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis [J]. J Heart Lung Transplant, 2019, 38(9): 949-955.
|
| 41 |
Salman J, Ius F, Sommer W, et al. Long-term results of bilateral lung transplantation in patients with end-stage pulmonary lymphangioleiomyomatosis [J]. Prog Transplant, 2019, 29(2): 115-121.
|
| 42 |
Li X, Xu W, Zhang L, et al. Effects of yoga on exercise capacity in patients with lymphangioleiomyomatosis: a nonrandomized controlled study [J]. Orphanet J Rare Dis, 2020, 15(1): 72.
|